Consider hypertriglyceridemia in congenital ichthyosis
Sara El-Ammari, Hanane Baybay, Imane Kacimi Alaoui, Sara Elloudi, Meryem Soughi, Zakia Douhi, Fatima Zahra Mernissi
Department of Dermatology, University Hospital Hassan II, Fes, Morocco
Citation tools:
Copyright information
© Our Dermatology Online 2024. No commercial re-use. See rights and permissions. Published by Our Dermatology Online.
Sir,
Chanarin–Dorfman syndrome (DCS) is a highly rare autosomal recessive inherited disorder caused by mutations in the ABHD5 gene (3p21) [1]. This results in the inhibition of the enzyme triglyceride lipase leading to lipid overload in various tissues, including the skin, muscle, liver, central nervous system, and blood leukocytes. This metabolic abnormality results in variable systemic manifestations such as congenital ichthyosiform non-bullous erythroderma, growth retardation, splenomegaly, steatohepatitis, cardiomyopathy, renal failure, sensorineural hearing loss, various ocular disorders such as cataract, nystagmus, retinal changes, and neurological impairment with proximal muscle weakness, areflexia, hypotonia, and mental retardation [1–3]. The muscle deficit remains subclinical in most cases, despite the elevation of muscle enzymes in more than 50% of cases. The diagnosis is based on the demonstration of Jordans bodies in leukocytes and muscles [1,2]. This syndrome is not too severe in the absence of neurological involvement [4]. The treatment of DCS is symptomatic and consists of the local application of emollients. A diet low in fatty acids and high in medium-chain triglycerides improves the cutaneous and hepatic manifestations [5]. Acitretin is useful in the treatment of skin and muscle manifestations with close monitoring of the lipid profile [3,5–7].
Herein, we report the case of a six-month-old infant from a consanguineous marriage presenting ichthyosis since birth and a history of a collodion baby. A general examination revealed a delay in the growth and development of the child. A dermatological examination revealed large, dark scales, not especially thick, over the entire body, sparing the large folds and face, with erythematous skin on the upper part of the trunk and the upper limbs (Fig. 1), associated with palmoplantar keratoderma (Figs. 2a and 2b), flattened ears, and ectropion. Biology revealed severe hypertriglyceridemia (3 g/L) rechecked on two occasions, creatine phosphokinase mb (CPK mb) five times the normal value, and CPK three times the normal value. Liver workup and renal function were normal, and a search for Jordans bodies in leukocytes was negative. An abdominal ultrasound was conducted, which revealed no evidence of hepatosplenomegaly or hepatic steatosis. However, due to insufficient resources, genetic tests could not be performed. Emollients were prescribed for the patient, who was subsequently lost to follow-up.
Our patient was diagnosed as a case of CDS based on the history of a baby collodion, congenital non-bullous ichthyosiform erythroderma with the elevation of muscle enzymes. Jordans bodies in leukocytes were negative, as was the case in an eight-year-old child reported by Arora [3]. Unfortunately, a mutation search could not be performed due to insufficient resources.
Consent
The examination of the patient was conducted according to the principles of the Declaration of Helsinki.
The authors certify that they have obtained all appropriate patient consent forms, in which the patients gave their consent for images and other clinical information to be included in the journal. The patients understand that their names and initials will not be published and due effort will be made to conceal their identity, but that anonymity cannot be guaranteed.
REFERENCES
1. Al-Hage J, Abbas O, Nemer G, Kurban M. Chanarin-Dorfman syndrome:A novel homozygous mutation in the ABHD5 gene. Clin Exp Dermatol. 2020;45:257-9.
2. Schweiger M, Lass A, Zimmermann R, Eichmann TO, Zechner R. Neutral lipid storage disease:Genetic disorders caused by mutations in adipose triglyceride lipase/PNPLA2 or CGI-58/ABHD5. Am J Physiol Endocrinol Metab. 2009;297:E289-96.
3. Arora S, Roy S, Arora D, Patil C, Jain AK. Chanarin–Dorfman syndrome with absent Jordan’s anomaly. Indian J Dermatol. 2017;62:549.
4. Turki C, Snoussi M, Damak C, Frikha F, Garbaa S, Hanen L, et al. Le syndrome de Dorfman Chanarin:àpropos d’une observation rare associant une atteinte cutanée et une myopathie. La Revue de Médecine Interne. 2018;39:A238.
5. AlNeyadi R, Abdelhadi S, Ruszczak Z. Chanarin–Dorfman syndrome treatment with acitretin. JAAD Case Rep. 2022;24:11-3.
6. Israeli S, Pessach Y, Sarig O, Goldberg I, Sprecher E. Beneficial effect of acitretin in Chanarin–Dorfman syndrome. Clin Exp Dermatol. 2012;37:31-3.
7. Mogahed EA, El-Hennawy A, El-Sayed R, El-Karaksy H. Chanarin–Dorfman syndrome:A case report and review of the literature. Arab J Gastroenterol. 2015;16:142-4.
Notes
Request permissions
If you wish to reuse any or all of this article please use the e-mail (contact@odermatol.com) to contact with publisher.
Related Articles | Search Authors in |
http://orcid.org/0000-0001-6330-2856
http://orcid.org/0000-0003-0582-321X
http://orcid.org/0000-0002-5942-441X
|
Comments are closed.